XM tidak menyediakan perkhidmatan kepada penduduk Amerika Syarikat.
U
U

UCB


Berita

Deals of the day-Mergers and acquisitions

Deals of the day-Mergers and acquisitions Adds: Asia Cement, McKesson Aug 26 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 1330 GMT on Monday: ** Asia Cement (China)'s 0743.HK shareholders have rejected its majority owner's take-private offer, it said. nL4N3KD0SV ** Drug distributor McKesson MCK.N said it would buy a controlling stake in community cancer center Florida Cancer Specialists & Research Institute's business and administrative services unit, Core
N
S
U
M

Deals of the day-Mergers and acquisitions

Deals of the day-Mergers and acquisitions Aug 26 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 0930 GMT on Monday: ** UCB UCB.BR , a Belgian biopharmaceutical firm, said it would sell its Chinese neurology and allergy business to Singapore-based asset management group CBC and Abu Dhabi sovereign investor Mubadala for $680 million.
N
S
U

Belgium's UCB to sell China neurology, allergy business for $680 mln

UPDATE 2-Belgium's UCB to sell China neurology, allergy business for $680 mln Acquisition includes anti-allergy medicines Zyrtec and Xyzal Deal expected to close in fourth quarter UCB to focus on innovation and partnerships Adds context in paragraph 7, advisers in final paragraph By Geert De Clercq and Yantoultra Ngui PARIS/SINGAPORE, Aug 26 (Reuters) - UCB UCB.BR , a Belgian biopharmaceutical firm, said on Monday it would sell its Chinese neurology and allergy business to Singapore-based asset
U

Mubadala Co-Invests In UCB's Mature Business In China

BRIEF-Mubadala Co-Invests In UCB's Mature Business In China Aug 26 (Reuters) - MUBADALA INVESTMENT [RIC:RIC:MUDEV.UL]: MUBADALA CO-INVESTS IN UCB'S MATURE BUSINESS IN CHINA TO REINFORCE ITS LONG-TERM COMMITMENT TO ASIAN MARKET CO IN PARTNERSHIP WITH CBC GROUP ACQUIRED 100% OWNERSHIP IN CARVE-OUT OF UCB PHARMA'S MATURE BUSINESS IN CHINA Further comp
U

Belgium's UCB sells China neurology and allergy business for $680 million

Belgium's UCB sells China neurology and allergy business for $680 million PARIS, Aug 26 (Reuters) - Belgian biopharmaceutical group UCB said in a statement it had agreed to sell its neurology and allergy business in China to Asian healthcare-dedicated asset management group CBC and Abu Dhabi-based investment company Mubadala for an amount of $680 million.
U

UCB To Divest Its Neurology And Allergy Business In China

BRIEF-UCB To Divest Its Neurology And Allergy Business In China Aug 26 (Reuters) - UCB SA UCB.BR : UCB TO DIVEST ITS MATURE NEUROLOGY AND ALLERGY BUSINESS IN CHINA, INCLUDING KEPPRA®, VIMPAT®, NEUPRO®, ZYRTEC® UCB TO DIVEST ITS MATURE NEUROLOGY AND ALLERGY BUSINESS IN CHINA, INCLUDING KEPPRA®, VIMPAT®, NEUPRO®, ZYRTEC®, XYZAL® AND ZHUHAI M
U

Top of the Street: UCB, Moncler, Sonova, Moncler, Voestalpine

BUZZ-Top of the Street: UCB, Moncler, Sonova, Moncler, Voestalpine A round-up of notable broker activity this morning from Europe's top-ranked* analysts: ** JP Morgan raises UCB UCB.BR to "overweight" from "neutral" as it sees the Belgian biotech firm's "superior growth profile" as "significantly" undervalued by the market; cites expected acceleration in Bimzelx growth ** Morgan Stanley downgrades Sonova SOON.S to "underweight" from "equal-weight", flagging the hearing aid maker's EV/EBITA valua
M
S
U
V
V

Admiral, UCB SA, Victrex

EUROPE RESEARCH ROUNDUP-Admiral, UCB SA, Victrex Aug 21 (Reuters) - Securities analysts revised their ratings and price targets on several European companies including Admiral, UCB SA and Victrex, on Wednesday. HIGHLIGHTS * Admiral ADML.L : RBC raises target price to 3,550p from 3,400p * Demant A/S DEMANT.CO : Morgan Stanley raises to overweight from underweight * UCB SA UCB.BR : JP Morgan raises to overweight from neutral * Victrex Plc VCTX.L : Jefferies raises to hold from underperform * Watki
A
A
C
H
I
M
N
R
S
S
U
V
V
A

AJ Bell, Avon Technologies, Hannover

EUROPE RESEARCH ROUNDUP-AJ Bell, Avon Technologies, Hannover Aug 20 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including AJ Bell, Avon Technologies and Hannover on Tuesday. HIGHLIGHTS * AJ Bell Plc AJBA.L : Morgan Stanley raises target price to 316p from 284p * Avon Technologies Plc AVON.L : Barclays raises target price to 1450p from 1400p * Hannover Re HNRGn.DE : Morgan Stanley raises target price to EUR 254 from EUR 252 * UCB SA UCB.B
A
A
B
B
C
H
H
H
H
K
P
R
R
S
S
T
U
W
P
N

UCB drops to bottom of BEL 20 after KBC downgrade

BUZZ-UCB drops to bottom of BEL 20 after KBC downgrade ** Shares in UCB UCB.BR fall 2.7% to the bottom of Belgium's BEL 20 .BFX blue-chip index after KBC Securities downgrades the biotech firm to "hold" from "accumulate" ** KBC says the downgrade is primarily caused by the substantial increase in UCB's share price, which has risen 135% from its Nov
U

Crest Nicholson, JDE Peet's, L'Oreal

EUROPE RESEARCH ROUNDUP-Crest Nicholson, JDE Peet's, L'Oreal Aug 14 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Crest Nicholson Holdings, JDE Peet's and L'Oreal, on Wednesday. HIGHLIGHTS * A.P. Moller-Maersk MAERSKb.CO : Deutsche Bank cuts PT to DKK 9217 from DKK 9283 * British American Tobacco Plc BATS.L : Barclays raises target price to 3100p from 2650p * Crest Nicholson Holdings Plc CRST.L : Peel Hunt cuts to hold from add *
A
B
C
C
D
E
E
E
H
J
L
N
R
S
S
T
U
U
U
A
E
F
P

UCB Announces EU Comission Approval For 320 Mg Devices Of Bimzelx[®]

BRIEF-UCB Announces EU Comission Approval For 320 Mg Devices Of Bimzelx[®] Aug 5 (Reuters) - Ucb SA UCB.BR : ANNOUNCES EUROPEAN COMMISSION APPROVAL FOR 320 MG DEVICE PRESENTATIONS OF BIMZELX[®] PATIENTS REQUIRING A 320 MG DOSE OF BIMEKIZUMAB WILL NOW HAVE AN ALTERNATIVE SINGLE-INJECTION OPTION OF BOTH PRE-FILLED SYRINGE AND PRE-FILLED PEN Source
U

Arkema, Man Group, Shell

EUROPE RESEARCH ROUNDUP- Arkema, Man Group, Shell Aug 2 (Reuters) - Securities analysts revised their ratings and price targets on several European companies including Arkema, Man Group and Shell, on Friday. HIGHLIGHTS * Arkema SA AKE.PA : HSBC raises target price to EUR 105 from EUR 103 * Berkeley Group BKGH.L : Jefferies raises target price to 4,936p from 4,834p * Diageo Plc DGE.L : Morgan Stanley cuts target price to 2200p from 2380p * Man Group Plc EMG.L : Peel Hunt cuts to add from buy * Sh
A
A
A
A
A
B
B
B
B
B
C
C
C
D
E
E
M
R
S
S
U
A
B
T

Greencore, UCB, Unilever

EUROPE RESEARCH ROUNDUP-Greencore, UCB, Unilever July 26 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Greencore, UCB, and Unilever, on Friday. HIGHLIGHTS * Greencore GNC.L : HSBC raises target price to 190p from 160p * Lonza Group AG LONN.S : JP Morgan raises target price to CHF 645 from CHF 600 * Sartorius Stedim Biotech STDM.PA : HSBC cuts target price to EUR 310 from EUR 360 * UCB SA UCB.BR : TD Cowen raises target price to E
A
A
A
B
B
B
B
B
C
D
D
E
G
G
G
L
N
N
P
R
S
U
A
A
A
A
A
A
B
D
J

UCB rises on H1 results 'clear beat'

BUZZ-UCB rises on H1 results 'clear beat' ** Shares in UCB UCB.BR rise 1.7%, pares gains after rising as much as 3%, after the Belgian biopharmaceutical group posted a "clear beat" in half-year results, says KBC ** "UCB's product sales land well ahead of consensus now that it is gaining steam across its 5 growth drivers, and especially Bimzelx," -
U

UCB SA Confirms Financial Guidance For 2024

BRIEF-UCB SA Confirms Financial Guidance For 2024 July 25 (Reuters) - Ucb SA UCB.BR : FINANCIAL GUIDANCE FOR 2024 CONFIRMED OUR 2025 COMMITMENT FOR GROWING TOP LINE TO AT LEAST EUR 6 BILLION AND A SIGNIFICANT IMPROVED MARGIN STANDS- CFO REVENUE IN FIRST HALF OF 2024 REACHED EUR 2.79 BILLION H1 UNDERLYING PROFITABILITY (ADJUSTED. EBITDA2) WAS EUR 65
U

UCB Announces Approval Of Its Epilepsy Drug Briviact In Japan

BRIEF-UCB Announces Approval Of Its Epilepsy Drug Briviact In Japan June 26 (Reuters) - Ucb SA UCB.BR : UCB'S EPILEPSY DRUG BRIVIACT(BRIVARACETAM) APPROVED IN JAPAN FOR TREATMENT OF FOCAL ONSET SEIZURES BRIVARACETAM WILL OFFER INCREASED TREATMENT CHOICE TO PHYSICIANS AND PATIENTS IN JAPAN LIVING WITH EPILEPSY Source text for Workspace: nNDL4zkFFf F
U

Hochtief, Telenor, Zalando SE

EUROPE RESEARCH ROUNDUP-Hochtief, Telenor, Zalando SE June 24 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Hochtief AG, Telenor and Zalando SE, on Monday. HIGHLIGHTS * Associated British Foods ABF.L : HSBC raises target price to 3,075p from 3,010p * Berkeley Group Holdings Plc BKGH.L : Morgan Stanley cuts PT to 4,369p from 4,516p * Hochtief AG HOTG.DE : Jefferies raises target price to EUR 124 from EUR 109 * Telenor TEL.OL : HSB
A
A
A
A
B
B
C
D
D
E
E
E
E
H
H
I
I
K
L
M
M
O
S
T
T
U
V
Z
A
A
A
B
F
L
R
S
S

Hargreaves Lansdown, Segro, Umicore

EUROPE RESEARCH ROUNDUP-Hargreaves Lansdown, Segro, Umicore June 19 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Hargreaves Lansdown, Segro and Umicore, on Wednesday. HIGHLIGHTS * GEA Group AG G1AG.DE : Jefferies raises to buy from hold * Hargreaves Lansdown HRGV.L : Jefferies cuts to hold from buy * Oxford Instruments OXIG.L : Berenberg raises target price to 2,945p from 2,640p * Segro SGRO.L : Jefferies cuts to hold from buy *
A
A
B
B
B
B
B
B
B
D
D
G
G
G
G
G
H
H
I
K
K
L
M
R
S
S
S
U
U
V
A
S

Takeda's seizure drug fails to meet main goal in late-stage studies

UPDATE 2-Takeda's seizure drug fails to meet main goal in late-stage studies Adds details in paragraphs 6-10, Ovid shares in paragraph 13, background throughout June 17 (Reuters) - Japanese drugmaker Takeda 4502.T TAK.N said on Monday its experimental drug being tested for two epileptic disorders failed to reduce frequency of seizures in patients across late-stage studies.
U



Syarat

Aset Popular

Penafian: Entiti XM Group menyediakan perkhidmatan pelaksanaan sahaja dan akses ke Kemudahan Dagangan Atas Talian, yang membolehkan sesorang melihat dan/atau menggunakan kandungan yang ada di dalam atau melalui laman web, tidak bertujuan untuk mengubah atau memperluas, juga tidak mengubah atau mengembangkannya. Akses dan penggunaan tersebut tertakluk kepada: (i) Terma dan Syarat; (ii) Amaran Risiko; dan Penafian Penuh. Oleh itu, kandungan sedemikian disediakan tidak lebih dari sekadar maklumat umum. Terutamanya, perlu diketahui bahawa kandungan Kemudahan Dagangan Atas Talian bukan permintaan, atau tawaran untuk melakukan transaksi dalam pasaran kewangan. Berdagang dalam mana-mana pasaran kewangan melibatkan tahap risiko yang besar terhadap modal anda.

Semua bahan yang diterbitkan di Kemudahan Dagangan Atas Talian kami bertujuan hanya untuk tujuan pendidikan/maklumat dan tidak mengandungi – dan tidak boleh dianggap mengandungi nasihat kewangan, cukai pelaburan atau dagangan dan cadangan, atau rekod harga dagangan kami, atau tawaran, atau permintaan untuk suatu transaksi dalam sebarang instrumen kewangan atau promosi kewangan yang tidak diminta kepada anda.

Sebarang kandungan pihak ketiga serta kandungan yang disediakan oleh XM, seperti pendapat, berita, penyelidikan, analisis, harga, maklumat lain atau pautan ke laman web pihak ketiga yang terdapat dalam laman web ini disediakan berdasarkan "seadanya" sebagai ulasan pasaran umum dan bukanlah nasihat pelaburan. Sesuai dengan apa-apa kandungan yang ditafsir sebagai penyelidikan pelaburan, anda mestilah ambil perhatian dan menerima bahawa kandungan tersebut tidak bertujuan dan tidak sediakan berdasarkan keperluan undang-undang yang direka untuk mempromosikan penyelidikan pelaburan bebas dan oleh itu, ia dianggap sebagai komunikasi pemasaran di bawah peraturan dan undang-undang yang berkaitan. SIla pastikan bahawa anda telah membaca dan memahami Notifikasi mengenai Penyelidikan Pelaburan Bukan Bebas dan Amaran Risiko mengenai maklumat di atas yang boleh diakses di sini.

Amaran Risiko: Modal anda dalam risiko. Produk yang berleveraj mungkin tidak sesuai untuk semua individu. Sila pertimbangkan Pendedahan Risiko kami.